Benitec Q1 net loss $5.1M, cash $16.5M; OPMD NH study screening starts Nov 2022

Benitec Biopharma Inc.

2023-Q1 EPS reported -$0.47

Net loss of $5.1M ($0.47 loss per share) for fiscal Q1 ended Sep 30, 2022.
Cash and cash equivalents of $16.5M as of Sep 30, 2022, up from $4.1M at Jun 30.
OPMD Natural History Study IRB approval received; subject screening begins Nov 2022 at US lead site.
BB-301 Phase 1b/2a IND/CTA filings planned for Q1 2023; first dosing expected Q2 2023.
R&D expenses $2.7M, G&A $1.9M for the quarter, both slightly down year-over-year.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Benitec Biopharma Inc. reported financial results for its fiscal quarter ended September 30, 2022.

Period: its fiscal quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 10, 2022 Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal quarter ended September 30, 2022.

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Benitec Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-281980

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.